Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Equity Average: 2013-2025

Historic Equity Average for Agios Pharmaceuticals (AGIO) over the last 12 years, with Sep 2025 value amounting to $1.3 billion.

  • Agios Pharmaceuticals' Equity Average rose 16.03% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 16.03%. This contributed to the annual value of $1.2 billion for FY2024, which is 23.02% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Equity Average stood at $1.3 billion, which was down 6.42% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Equity Average ranged from a high of $2.0 billion in Q2 2021 and a low of $702.2 million during Q2 2024.
  • For the 3-year period, Agios Pharmaceuticals' Equity Average averaged around $1.1 billion, with its median value being $1.1 billion (2023).
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 239.46% in 2021, then tumbled by 41.98% in 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Equity Average (Quarterly) stood at $1.3 billion in 2021, then dropped by 19.94% to $1.1 billion in 2022, then declined by 21.07% to $848.9 million in 2023, then spiked by 86.57% to $1.6 billion in 2024, then increased by 16.03% to $1.3 billion in 2025.
  • Its Equity Average stands at $1.3 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.5 billion for Q1 2025.